ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0802 • ACR Convergence 2020

    Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness

    Yoshiya Tanaka1, Hisashi Yamanaka2, Leslie Harrold3, Tin-chi Lin3, Ekta Agarwal4, Jose L Rivas5, Naonobu Sugiyama6, Jeffrey Greenberg7 and Mitsumasa Kishimoto8, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 2Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, 3Corrona, LLC, Waltham, MA, 4Pfizer, Inc., Princeton Jct, NJ, 5Pfizer SLU, Madrid, Spain, 6Pfizer Japan Inc, Tokyo, Japan, 7Corrona, LLC and NYU School of Medicine, Waltham, MA, 8Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan

    Background/Purpose: There are several conventional synthetic, targeted synthetic and biological disease-modifying anti-rheumatic medications (DMARDs) approved for the treatment of rheumatoid arthritis (RA) in Japan. Little…
  • Abstract Number: 0801 • ACR Convergence 2020

    The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study

    Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Xue Han2, Joe Zhuo2, Amy Schrader1, Nicole Middaugh1, Page Moore1 and Vadim Khaychuk2, 1Corrona, LLC, Waltham, MA, 2Bristol-Myers Squibb Company, Princeton, NJ

    Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
  • Abstract Number: 0807 • ACR Convergence 2020

    Safety of Biologic & Targeted Therapies Among Elderly Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Akhil Sood1, Soham Al Snih1, Vijaya Murthy2, Emilio Gonzalez1 and Mukaila Raji1, 1University of Texas Medical Branch, Galveston, TX, 2University of Texas Medical Branch, League City, TX

    Background/Purpose: Recent developments in biologic and targeted therapy have led to better control of disease activity and improved quality of life in patients with rheumatoid…
  • Abstract Number: 0806 • ACR Convergence 2020

    Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy

    Anthony Cordisco1 and Joshua Baker1, 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Numerous clinical trials have been published in rheumatoid arthritis (RA), but comparing efficacies of disease-modifying anti-rheumatic drugs (DMARDs) is complicated by a lack of…
  • Abstract Number: 0812 • ACR Convergence 2020

    Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US

    Simon Helfgott1, Janna Radtchenko2, Nehad Soloman3, Kent Kwas Huston4, Jasvinder Singh5 and Colin Edgerton6, 1BWH- HMS, Boston, MA, 2Trio Health, Louisville, CO, 3Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, 4Kansas City Physician Partners, Kansas City, MO, 5University of Alabama at Birmingham, Birmingham, AL, 6Articularis Healthcare, Summerville, SC

    Background/Purpose: Biologics have revolutionized the treatment of autoimmune diseases, though costs and payer restrictions have limited who are treated and when these agents are used. …
  • Abstract Number: 0814 • ACR Convergence 2020

    “I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic

    Rishi Gupta1, Muhammad Shipa2, Su-Ann Yeoh2, Pauline Buck1 and Michael Ehrenstein2, 1University College London Hospital, London, United Kingdom, 2University College London, LONDON, United Kingdom

    Background/Purpose: During the COVID-19 pandemic, rapid guidelines by the National Institute for Health and Care Excellence (NICE) in the United Kingdom[1] recommended consideration of switching…
  • Abstract Number: 0809 • ACR Convergence 2020

    Comparative Effectiveness of Intravenous Golimumab vs Dose-Escalated Infliximab in a Real World Population of Rheumatoid Arthritis Patients: 52-Week Data from the AWARE Study

    Sergio Schwartzman1, Shelly Kafka2, Douglas Conaway3, Aaron Broadwell4, Shawn Black2, Stephen Xu5, Wayne Langholff6 and Jeffrey R Curtis7, 1Weill Cornell Medical College, New York, NY, 2Janssen Scientific Affairs, LLC, Horsham, PA, 3Grand Strand Regional Medical Center, Myrtle Beach, SC, 4Rheumatology and Osteoporosis Specialists, Shreveport, LA, 5Janssen Research & Development, LLC, Spring House, 6Janssen Research & Development, LLC, Spring House, PA, 7Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is a Phase 4, prospective, noninterventional, observational, multicenter (88 sites), 3-year…
  • Abstract Number: 0804 • ACR Convergence 2020

    Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands

    Elise van Mulligen1, Saad Ahmed1, Angelique Weel2, Mieke Hazes3, Annette van der Helm - van Mil4 and Pascal de Jong1, 1Erasmus MC, Rotterdam, Netherlands, 2Erasmus School of Health Policy & Management, Maasstad hospital, Erasmus MC, Rotterdam, Netherlands, 3Erasmus Medical Center, Rotterdam, Netherlands, 4Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Data on biological survival, stratified for discontinuation reasons, and predictors that influence survival time have not been explored extensively. Therefore, we aim to explore…
  • Abstract Number: 0817 • ACR Convergence 2020

    Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia

    Geoffrey Littlejohn1, Tegan Smith2, Kathleen Tymms3, Peter Youssef4, Helen Cooley5, Sabina Ciciriello6, David Mathers7, Catherine OSullivan2 and Hedley Griffiths8, 1Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia, 2OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, 3Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, 4University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia, 5Hobart Private Hospital, Hobart, TAS, Taroona, Australia, 6Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, 7Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, 8Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia

    Background/Purpose: JAK inhibitors (JAKi) are targeted synthetic DMARDs (tsDMARDs) with a different mode of action (MOA) to conventional synthetic and biologic DMARDs (cs and bDMARDs).…
  • Abstract Number: 0820 • ACR Convergence 2020

    High Remission Rates in RA – Real Life Data from Bariticinib

    Sara Bayat1, Koray Tascilar2, Arnd Kleyer2, David Simon2, Axel Hueber3 and Georg Schett4, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 3Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, 4Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Recent developments of targeted treatments such as targeted synthetic DMARDs (tsDMARDs) increase the chances of a sustained low disease activity (LDA) or remission state…
  • Abstract Number: 0821 • ACR Convergence 2020

    Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry

    Vijaya Rivera1, Sandra Sicsik Ayala1, David Vega Morales2, Fedra Irazoque-Palazuelos3, Dafhne Miranda Hernández1, Julio Casasola Vargas1, Sandra Carrillo Vázquez1, Angélica Peña Ayala1, Angel Castillo Ortiz1, Omar Muñoz Monroy1, Sergio Durán Barragán1, Aleni Paz Viscarra1, Estefanía Torres Valdez1, Daniel Xibille Friedmann1, Erick A Zamora Tehozol4, Luis Valdés Corona1, Azucena Ramos Sánchez1, Natalia Santana Portillo1, Francisco Guerrero Díaz1, Miguel Vazquez Zaragoza1, Claudia Zepeda Moreno1, Kitzia Alvarado Sánchez1, Melanea Rivera Valencia1, Cesar Pacheco Tena5 and Deshire Alpizar-Rodriguez6, 1Colegio Mexicano de Reumatología, Mexico City, Mexico, 2Universidad Autónoma de Nuevo León, Garcia, Mexico, 3Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, 4Centro Médico Pensiones, Merida, Yucatan, Mexico, 5Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, 6Colegio Mexicano de Reumatología, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and is more frequent and severe in women than in men. Symptom severity, disease progression,…
  • Abstract Number: 0816 • ACR Convergence 2020

    Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry

    Jakub Závada1 and Lucie Nekvindova2, 1Revmatologický ústav, Praha 2, Czech Republic, 2Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic

    Background/Purpose: Treat-to-target (T2T) is a widely accepted management strategy for RA. It recommends attaining a goal of at least low disease activity (LDA) within 6…
  • Abstract Number: 0824 • ACR Convergence 2020

    The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study

    Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Xue Han2, Ying Shan1, Page Moore1, Lin Guo1 and Vadim Khaychuk2, 1Corrona, LLC, Waltham, MA, 2Bristol-Myers Squibb Company, Princeton, NJ

    Background/Purpose: Previous data from the Corrona RA registry, conducted in a US clinical practice setting, demonstrated that patients (pts) with RA who were ACPA+ had…
  • Abstract Number: 0819 • ACR Convergence 2020

    The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar

    Joseph Alanaeme1, Sujith Sarvesh1, Jeffrey R Curtis2 and Huifeng Yun2, 1University of Alabama at Birmingham, BIrmingham, AL, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Infliximab (INF) biosimilar was approved for multiple indications in U.S. in 2016. Although clinical trials have demonstrated that switching from infliximab bio-originator to its…
  • Abstract Number: 0711 • ACR Convergence 2020

    Alternative Dosing of Biologic Therapies Is Frequent Among Children with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Colleen Correll1, Peter Shrader2, Anne Dennos3, Thomas Phillips2, Natalie Shiff4, Ruud Verstegen5 and Timothy Beukelman6, 1University of Minnesota, Minneapolis, MN, 2Duke University, Durham, 3Duke University, Durham, NC, 4Florida, Gainesville, FL, 5The Hospital for Sick Children, Toronto, ON, Canada, 6University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Biologic agents are integral to the treatment of juvenile idiopathic arthritis (JIA) and associated uveitis. Pediatric rheumatologists may increase the dosage of biologics beyond…
  • « Previous Page
  • 1
  • …
  • 679
  • 680
  • 681
  • 682
  • 683
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology